Valneva Austria GmbH
Clinical Trials
51
Trial Phases
4 Phases
Drug Approvals
2
Clinical Trials
Distribution across different clinical trial phases (44 trials with phase data)• Click on a phase to view related trials
Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults
- Conditions
- ZikaZika Virus Infection
- Interventions
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Valneva Austria GmbH
- Target Recruit Count
- 150
- Registration Number
- NCT06334393
- Locations
- 🇺🇸
Flourish Research, Chicago, Illinois, United States
🇺🇸Velocity Clinical Research, Omaha, Nebraska, United States
A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years
- Conditions
- Chikungunya Virus Infection
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Valneva Austria GmbH
- Target Recruit Count
- 304
- Registration Number
- NCT06106581
- Locations
- 🇩🇴
Fundacion Dominicana de Perinatologia Fundacion Probebe, Santo Domingo, Gazcue, Dominican Republic
🇩🇴Instituto Dermatologico y Cirugia de la Piel "Dr Huberto Bogaert Diaz" IDCP, Santo Domingo, Dominican Republic
🇭🇳Inversiones en Investigacion Medica INVERIME, Tegucigalpa, Honduras
A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV)
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Valneva Austria GmbH
- Target Recruit Count
- 75
- Registration Number
- NCT06028841
VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection
- Conditions
- SARS-CoV-2 Infection
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Valneva Austria GmbH
- Target Recruit Count
- 178
- Registration Number
- NCT05364242
- Locations
- 🇳🇱
General Practitioners Research Institute (GPRI), Groningen, Netherlands
🇳🇱European Clinical Research Alliance on Infectious Diseases (ECRAID), Utrecht, Netherlands
🇳🇿Middlemore Clinical Trials, Auckland, Papatoetoe, New Zealand
COVID-19 Paediatric VLA2001-321 Study
- Conditions
- SARS-CoV-2 Infection
- Interventions
- Biological: VLA2001Drug: Active Comparator
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Valneva Austria GmbH
- Registration Number
- NCT05298644
- Prev
- 1
- 2
- 3
- 4
- 5
- 8
- Next
News
VLA1553 Chikungunya Vaccine Shows Durable Antibody Response at Two Years
A phase 3b trial of VLA1553 showed that chikungunya virus-neutralizing antibodies persisted for up to two years post-vaccination.